BiotechTube
Biocartis

Biocartis

BCART
Mechelen, Belgium· Est.
biocartis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

Founded in 2007, Biocartis has established itself as a leader in automated, rapid molecular diagnostics with its proprietary Idylla™ platform. Its core mission is to make molecular testing actionable, easy, fast, and suitable for any lab, thereby enabling personalized medicine worldwide. Key achievements include securing FDA approval for its Idylla MSI Test and building a broad menu of RUO and IVD assays, primarily in oncology. The company's strategy revolves around expanding its test menu, deepening market penetration in the US and Europe, and leveraging partnerships to drive platform adoption.

OncologyInfectious Diseases

Technology Platform

The Idylla™ platform is a fully automated, sample-to-answer, real-time PCR (qPCR) system that uses disposable cartridges to deliver molecular diagnostic results from raw samples in 90 minutes to 3 hours, requiring minimal manual intervention.

Funding History

4
Total raised:$200M
IPO$100M
Series C$50M
Series B$30M
Series A$20M

Opportunities

The core opportunity lies in the decentralization of molecular testing from large reference labs to local hospitals, driven by the need for faster treatment decisions in oncology.
The growing number of targeted therapies and immunotherapies requiring biomarker testing creates a continuous demand for new, rapid companion diagnostics.
The platform's proven utility also opens optionality in infectious disease and other therapeutic areas.

Risk Factors

Key risks include intense competition from larger, resource-rich diagnostics companies, the challenge of securing favorable reimbursement for tests, and regulatory hurdles for new assay approvals.
The company's financial sustainability depends on successfully scaling its commercial operations to achieve profitability, and its fortunes remain heavily concentrated on a single technology platform.

Competitive Landscape

Biocartis competes with large integrated diagnostics firms (Roche, Abbott, Qiagen) offering automated systems, and with specialized oncology profiling companies using NGS (Foundation Medicine, Guardant Health). Its primary competitive advantages are the Idylla platform's exceptional speed (90 min - 3 hrs), true ease of use for any lab, and focused menu tailored for rapid, actionable results in oncology.

More companies in Diagnostics & Precision Medicine →More companies in Belgium →